LV10502B - Novel fungal strain and use thereof in preparation of antibiotics - Google Patents

Novel fungal strain and use thereof in preparation of antibiotics Download PDF

Info

Publication number
LV10502B
LV10502B LVP-93-115A LV930115A LV10502B LV 10502 B LV10502 B LV 10502B LV 930115 A LV930115 A LV 930115A LV 10502 B LV10502 B LV 10502B
Authority
LV
Latvia
Prior art keywords
lovastatin
strain
orvzae
aspergillus
dna
Prior art date
Application number
LVP-93-115A
Other languages
English (en)
Other versions
LV10502A (lv
Inventor
Jagroop S Dahiya
Original Assignee
Novopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA002062023A external-priority patent/CA2062023A1/en
Application filed by Novopharm Ltd filed Critical Novopharm Ltd
Publication of LV10502A publication Critical patent/LV10502A/lv
Publication of LV10502B publication Critical patent/LV10502B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/02—Oxygen as only ring hetero atoms
    • C12P17/06—Oxygen as only ring hetero atoms containing a six-membered hetero ring, e.g. fluorescein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
    • C12P7/42—Hydroxy-carboxylic acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A20/00—Water conservation; Efficient water supply; Efficient water use
    • Y02A20/40—Protecting water resources
    • Y02A20/402—River restoration

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Claims (6)

  1. LV 10502 Formula 1, Lovastatīna iegūšanas paņēmiens, kas ietver sevī kā barotnes fermentēšanu ar transformētu mikroskopiskās sēnes Aspergillus celmu, kas selekcionēts no A.oryzae, A.niger, A.nidulans. A. fumigatus un A.flavus sugu grupas, kuras celms nespēj ekspre-sēt lovastatīnu, bet kuru var transformēt, lai saturētu svešu DNS, kas kodē lovastatīnu sintezēt spējīgu fermentu kompleksu un selektīvu marķieri, tā arī lovastatīna izdalīšanu no barotnes· 2e 1.punktā aprakstītais paņēmiens, kur transformētais mikroorganisms satur svešu DNS, kas iegūta no lovastatīnu producējošas Aspergillus terreus sugas. 3. 2.punktā aprakstītais paņēmiens, kur iepriekšminētais Asper-gillus celms ir A.orvzae sugas celms.
  2. 4. Jebkurā iepriekšējā punktā aprakstītais paņēmiens, kur svešās DNS, ko ievada transformantā, kā selektīvo marķieri satur cikloheksimīda rezistences gēnus.
  3. 5. Jebkurā iepriekšējā punktā aprakstītais paņēmiens, kur trans-formants ir AoAt-NBJ/5 kā aprakstīts un definēts.
  4. 6. Jebkurā iepriekšējā punktā aprakstītais paņēmiens, kas satur lovastatīna fermentēšanas procesā radušās hidroksiskābes analoga laktonizēšanas papildus etapu.
  5. 7. Jebkurā iepriekšējā punktā aprakstītais paņēmiens, kur lovastatīna izdalīšanu veic, ekstragējot ar šķīdinātāju.
  6. 8. Jauni sēņu transformanti, kas satur lovastatīnu sintezējošo fermentu kompleksu, iepriekšminētie transformanti no Aspergillus sp. izcelsmes celmiem, kas izdalīti no A.orvzae. A. niger, A.nidulans. A.fumigatus un A.flavus un kas sākotnēji nespēj ekspreset lovastatīnu, bet kas satur svešu DNS ar lovastatīnu sintezēt spējīgu fermentu kompleksu kodējošiem gēniem. •9. 8.punktā aprakstītie sēņu transformanti, kur Aspergillus sp. ir selekcionēts no grupas, kurā ietilpst A.orvzae. A.niger , A.nidulans un A.fumigatus. 10. 9.punktā aprakstītie sēņu transformanti, kur Aspergillus sp. ir A.orvzae.. 2 11. 10,punktā aprakstītie sēņu transformanti, kur svešā DMS iegūta no lovastatīnu ekspresējoša Asnergillus terreus sugas celma. 12. 11.punktā aprakstītie sēņu transformanti un tādi sēņu transformanti, kas satur iepriekšminētā A.terreus celma summārās DNS protoplastu transformācijas produktu iepriekšminētā A.orvzae celmā. 13. Sēņu transformanti AoAt-NBJ/5 kā aprakstīts un definēts.
LVP-93-115A 1992-02-10 1993-02-10 Novel fungal strain and use thereof in preparation of antibiotics LV10502B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83349692A 1992-02-10 1992-02-10
CA002062023A CA2062023A1 (en) 1992-02-10 1992-02-27 Novel fungal strains and use thereof in antibiotic production

Publications (2)

Publication Number Publication Date
LV10502A LV10502A (lv) 1995-02-20
LV10502B true LV10502B (en) 1995-08-20

Family

ID=25674996

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-93-115A LV10502B (en) 1992-02-10 1993-02-10 Novel fungal strain and use thereof in preparation of antibiotics

Country Status (18)

Country Link
EP (1) EP0556699A1 (lv)
JP (1) JPH0622780A (lv)
CN (1) CN1076965A (lv)
AU (1) AU667498B2 (lv)
BG (1) BG61180B1 (lv)
BR (1) BR9300467A (lv)
CZ (1) CZ17293A3 (lv)
EE (1) EE03048B1 (lv)
FI (1) FI930561A (lv)
HR (1) HRP930134A2 (lv)
HU (1) HUT67061A (lv)
IL (1) IL104481A0 (lv)
LV (1) LV10502B (lv)
NO (1) NO930446L (lv)
NZ (1) NZ245713A (lv)
PL (1) PL297691A1 (lv)
SI (1) SI9300068A (lv)
SK (1) SK5593A3 (lv)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100054A (en) * 1989-05-05 2000-08-08 Baylor College Of Medicine Production for recombinant lactoferrin and lactoferrin polypeptides using DNA sequences in various organisms
IL94183A (en) 1989-05-05 2003-09-17 Baylor College Medicine cDNA SEQUENCE CODING FOR HUMAN LACTOFERRIN PROTEIN OR PORTION THEREOF AND LACTOFERRIN PROTEIN PRODUCED FROM SAID SEQUENCE
US5571691A (en) * 1989-05-05 1996-11-05 Baylor College Of Medicine Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms
US5849881A (en) * 1989-05-05 1998-12-15 Baylor College Medicine Production of recombinant lactoferrin and lactoferrin polypeptides using cDNA sequences in various organisms
US5766939A (en) * 1989-05-05 1998-06-16 Baylor College Of Medicine Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms
SI9300303A (en) * 1993-06-08 1994-12-31 Krka Tovarna Zdravil Process for isolation of hypolipemic effective substance
EP0726940A4 (en) * 1993-11-02 2001-05-23 Merck & Co Inc DNA ENCODING A TRIOL-POLYCETIDE-SYNTHASE
US6221637B1 (en) 1996-03-05 2001-04-24 Takeda Chemical Industries, Ltd. Xanthene derivatives, their production and use
US6111081A (en) * 1996-05-31 2000-08-29 Baylor College Of Medicine Lactoferrin variants and uses thereof
CZ299290B6 (cs) * 1997-02-20 2008-06-11 Dsm Ip Assets B.V. Zpusob výroby beta-laktamové slouceniny, zpusob prípravy a/nebo zlepšení vláknitého mikrobiálního kmene a použití chemicky definovaného fermentacníhomédia
IL132822A0 (en) * 1998-03-20 2001-03-19 Biogal Gyogyszergyar Metabolic controlled fermentation procedure for the manufacture of lovastatin hydroxy acid
US6391583B1 (en) * 1998-12-18 2002-05-21 Wisconsin Alumni Research Foundation Method of producing antihypercholesterolemic agents
EP1176208A1 (en) * 2000-07-28 2002-01-30 Société des Produits Nestlé S.A. Koji molds and use thereof for preparing cholesterol-lowering products
DE60218822T2 (de) * 2001-02-09 2007-07-12 Unilever N.V. Nahrungsmittel enthaltend sojaprotein und statin
KR100423892B1 (ko) * 2001-12-03 2004-03-22 씨제이 주식회사 스타틴의 제조에 있어서 새로운 락톤화 방법
WO2006035295A1 (en) * 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Process for the purification of lovastatin
CN102533893A (zh) * 2010-12-09 2012-07-04 浙江海正药业股份有限公司 一种制备莫那可林j的方法
CN104277980B (zh) * 2013-07-09 2020-04-21 丰益(上海)生物技术研发中心有限公司 分离纯化米曲霉转化子的方法
CN105602856B (zh) * 2015-12-16 2019-04-16 浙江师范大学 黑曲霉（Aspergillus niger）An-19菌株及其用于洛伐他汀的生产的用途和发酵方法
CN108118042B (zh) * 2016-11-30 2021-01-15 中国科学院青岛生物能源与过程研究所 2-甲基丁酸侧链水解酶和产莫纳可林j的曲霉菌株及其构建方法与应用
CN111117894B (zh) * 2019-11-26 2023-11-10 漳州大北农农牧科技有限公司 一株米曲霉菌株及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU535944B2 (en) * 1979-06-15 1984-04-12 Merck & Co., Inc. Hypocholestermic fermentation products from aspergillus
WO1987003907A1 (en) * 1985-12-17 1987-07-02 Lubrizol Genetics, Inc. Isolation of genes for biosynthesis of polyketide antibiotics
FI104984B (fi) * 1988-08-11 2000-05-15 Dsm Nv Menetelmä biosynteettisten tai säätelygeenien identifioimiseksi ja käyttämiseksi sekundääristen metaboliittien tuoton parantamiseksi

Also Published As

Publication number Publication date
FI930561A0 (fi) 1993-02-09
CZ17293A3 (en) 1993-12-15
EE03048B1 (et) 1997-10-15
BR9300467A (pt) 1993-08-17
BG97421A (bg) 1994-03-24
CN1076965A (zh) 1993-10-06
JPH0622780A (ja) 1994-02-01
SI9300068A (en) 1993-09-30
HRP930134A2 (en) 1995-10-31
NZ245713A (en) 1994-12-22
EP0556699A1 (en) 1993-08-25
NO930446L (no) 1993-08-11
AU3212193A (en) 1993-08-12
HUT67061A (en) 1995-01-30
BG61180B1 (bg) 1997-02-28
NO930446D0 (no) 1993-02-09
HU9300330D0 (en) 1993-04-28
LV10502A (lv) 1995-02-20
IL104481A0 (en) 1993-05-13
SK5593A3 (en) 1993-12-08
PL297691A1 (en) 1994-01-24
AU667498B2 (en) 1996-03-28
FI930561A (fi) 1993-08-11

Similar Documents

Publication Publication Date Title
LV10502B (en) Novel fungal strain and use thereof in preparation of antibiotics
US5362638A (en) Fungal strains and use thereof in antibiotic production
US5250435A (en) Mutant strains of Aspergillus terreus for producing 7-[1,2,6,7,8,8a(R)-hexa-hydro-2(S),6(R)-dimethyl-8(S)-hydroxy-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid (triol acid),I)
US6943017B2 (en) Method of producing antihypercholesterolemic agents
Kieslich Biotransformations of industrial use
JP3645491B2 (ja) プラバスタチンの微生物学的製法
EP1015600A1 (en) Statin production by fermentation
US4952604A (en) Antifungal agent
EP0842290A1 (en) Process for the preparation of lovastatin
KR100186758B1 (ko) 프라바스타틴(pravastatin)전구체의제조방법
GB2079279A (en) Process for preparing a macrolide
WO2008092950A1 (en) Fermentation process for preparing pravastatin
EP1799808B1 (en) Process for producing mycophenolic acid using penicillium arenicola bicc7673
US7189558B2 (en) Process for producing pravastatin sodium salt using streptomyces flavidovirens dsm 14455
RU2252258C2 (ru) Микробный способ получения правастатина
KR100234976B1 (ko) 세룰레닌 및 엘-메치오닌 유사체에 동시 내성을 갖는 아스퍼질 러스속 미생물 및 그를 이용한 메비놀린산의 제조방법
NO863077L (no) Fremgangsmaate til mikrobiell hydroksylering av forskolin og dens derivater ved neurospora crassa.
Sridharan et al. Guru raja et al.
CZ2000512A3 (cs) Způsob mikrobiální oxidace 2-methylchinoxalinu na 2-chinoxalinkarboxylovou kyselinu